UK Medtech To Leverage Accelerated Access Opportunity, Regardless Of The 'B' Word

Little in current UK political and economic decision-making is outside the shadow of Brexit, on the horizon and moving ever closer – according to the original script. So it is tempting to look at the 18-page response from the UK Departments of Health (DoH), and Business, Energy and Industrial Strategy (BEIS) to Sir Hugh Taylor and Professor Sir John Bell's considered Accelerated Access Review through this lens: How far is this element of the UK Life Sciences strategy (Also see "Moonshot Projects In Life Sciences Strategy Can Lift UK Over Brexit Hurdle" - Medtech Insight, 30 August, 2017.) a proactive, high-level shoring-up exercise, and how much of it will be of practical use to UK medtech innovators on the ground?

As far as the high-level AAR news of last week is concerned – the new Accelerated Access Pathway (AAP) – most medtech innovation may be on the outside looking in